4:34 PM
 | 
Jul 08, 2013
 |  BC Extra  |  Company News

EMA to review insulin glargine analog from Lilly, Boehringer

Eli Lilly and Co. (NYSE:LLY) and partner Boehringer Ingelheim GmbH (Ingelheim, Germany) said EMA accepted for review an MAA for LY2963016...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >